A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of CNP520 in Healthy Elderly Subjects
Phase of Trial: Phase II
Latest Information Update: 31 May 2017
At a glance
- Drugs CNP 520 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 21 Jul 2016 This trial was "discontinued" in Netherlands, according to European Clinical Trials Database.
- 26 Apr 2016 Status changed from recruiting to completed.